公衆衛生80巻6号

2016年06月発行

特集 難病対策

神経難病と再生医療

著者： 土井大輔¹ 髙橋淳¹²

所属機関： ¹京都大学iPS細胞研究所 臨床応用研究部門 ²京都大学医学部附属病院 脳神経外科

ページ範囲：P.419 - P.424

　2007年にヒトiPS(induced pluripotent stem)細胞が樹立されて以来，iPS細胞を用いた再生医療を臨床応用するための研究が急速に進んできた．日本では2013年に，滲出型加齢黄斑変性症の患者に対して，iPS細胞由来の網膜色素上皮細胞の自家移植が世界に先駆けて行われた．神経系の疾患では，パーキンソン病や脊髄損傷，脳梗塞等が次の細胞移植の候補として挙げられている．われわれはパーキンソン病をターゲットとして，iPS細胞由来ドパミン神経前駆細胞の細胞移植治療の臨床応用を目指しており，本稿ではこれまでの研究の成果と今後の展望について述べたい．

参考文献

1)厚生労働省：平成26年　患者調査．厚生労働省大臣官房統計情報部　http://www.mhlw.go.jp/toukei/saikin/hw/kanja/10syoubyo

2)厚生労働省：平成25年　国民生活基礎調査の概況．大臣官房統計情報部人口動態・保健社会統計課世帯統計室，平成26年7月15日　http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa13/dl/16.pdf

3)Wenning GK, et al:Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42(1):95-107, 1997

4)Hagell P, et al:Sequential bilateral transplantation in Parkinson's disease:effects of the second graft. Brain 122:1121-1132, 1999

5)Hauser RA, et al:Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56(2):179-187, 1999

6)Piccini P, et al:Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2(12):1137-1140, 1999

7)Brundin P, et al:Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123:1380-1390, 2000

8)Freed CR, et al:Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344(10):710-719, 2001

9)Olanow CW, et al:A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54(3):403-414, 2003

10)Mendez I, et al:Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128:1498-1510, 2005

11)Thomson JA, et al:Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147, 1998

12)Takahashi K, et al:Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861-872, 2007

13)Okita K, et al:A more efficient method to generate integration-free human iPS cells. Nat Methods 8(5):409-412, 2011

14)Nakagawa M, et al:Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A 107(32):14152-14157, 2010

15)Okita K, et al:An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 31(3):458-466, 2013

16)Kriks S, et al:Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480:547-551, 2011

17)Kirkeby A, et al:Generation of Regionally Specified Neural Progenitors and Functional Neurons from Human Embryonic Stem Cells under Defined Conditions. Cell Rep 1(6):703-714, 2012

18)Doi D, et al:Prolonged Maturation Culture Favors a Reduction in the Tumorigenicity and the Dopaminergic Function of Human ESC-Derived Neural Cells in a Primate Model of Parkinson's Disease. Stem Cells 30(5):935-945, 2012

19)Miyazaki T, et al:Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat Commun 3:1236, 2012

20)Nakagawa M, et al:A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci Rep 4:3594, 2014

21)Doi D, et al:Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2(3):337-350, 2014

22)Nguyen HN, et al:LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8(3):267-280, 2011